Generix Group (GENX.PA) Stock Price
Generix Group Price
Revenue has compounded at 9.1% per year over the past 19 years to 84.50 M EUR. Earnings per share have grown at 0.5% per year over the last 14 years. Generix Group's net margin stands at 4.0%, up from 0.8% several years earlier.
Generix Group stock price
Generix Group Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.00 | 64.00 | 64.00 | 50.00 | 55.00 | 59.00 | 64.00 | 70.00 | 76.00 | 81.00 | 80.00 | 84.00 | 90.00 | 96.00 | 98.00 | 99.00 |
| -2.94 | -3.03 | – | -21.88 | 10.00 | 7.27 | 8.47 | 9.38 | 8.57 | 6.58 | -1.23 | 5.00 | 7.14 | 6.67 | 2.08 | 1.02 |
| 96.97 | 96.88 | 70.31 | 70.00 | 69.09 | 66.10 | 65.63 | 67.14 | 69.74 | 72.84 | 77.50 | 78.57 | 78.57 | 78.57 | 78.57 | 78.57 |
| 64.00 | 62.00 | 45.00 | 35.00 | 38.00 | 39.00 | 42.00 | 47.00 | 53.00 | 59.00 | 62.00 | 66.00 | 70.71 | 75.43 | 77.00 | 77.79 |
| -5.00 | – | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 4.00 | 9.00 | 6.00 | 6.00 | 6.00 | 8.00 | 8.00 | 8.00 |
| -7.58 | – | 4.69 | 6.00 | 7.27 | 5.08 | 3.13 | 2.86 | 5.26 | 11.11 | 7.50 | 7.14 | 6.67 | 8.33 | 8.16 | 8.08 |
| -5.00 | -2.00 | 1.00 | 3.00 | – | 1.00 | – | – | 2.00 | 3.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 |
| 150.00 | -60.00 | -150.00 | 200.00 | – | – | – | – | – | 50.00 | 66.67 | -40.00 | – | 33.33 | – | – |
| 14.25 | 21.13 | 27.18 | 26.43 | 22.69 | 22.69 | 22.69 | 22.69 | 13.69 | 22.62 | 22.69 | 22.69 | 22.69 | 22.69 | 22.69 | 22.69 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Generix Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Generix Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Generix Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Generix Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Generix Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Generix Group business model & stock analysis
Generix Group SWOT Analysis
Strengths
Generix Group SA possesses several strengths that contribute to its success in the market. These include:
- Strong Market Presence: Generix Group SA has established a solid presence in the industry, with a wide customer base and a reputable brand.
- Product Innovation: The company is known for its continuous investment in research and development, resulting in innovative and cutting-edge solutions.
- Skilled Workforce: Generix Group SA has a highly skilled and experienced workforce that enables efficient operations and effective customer support.
- Global Footprint: With an international presence, Generix Group SA has the opportunity to tap into diverse markets and expand its reach.
Weaknesses
Despite its strengths, Generix Group SA also has several weaknesses that may hinder its growth and competitiveness. These include:
- Dependency on Key Customers: The company relies heavily on a few major clients, which creates vulnerability in case of loss or dissatisfaction of these customers.
- Limited Product Portfolio: Generix Group SA's product offerings are primarily focused on specific segments, limiting its ability to cater to a broader range of industries and customer needs.
- High Reliance on Technology: The company heavily relies on technology for its solutions, making it susceptible to disruptions or technological advancements that may render its products obsolete.
- Competitive Market: Generix Group SA faces intense competition from other industry players, which may impact its market share and profitability.
Opportunities
Generix Group SA has identified several opportunities that can be leveraged to its advantage. These include:
- Emerging Markets: Expansion into emerging markets presents significant growth opportunities for Generix Group SA, where demand for its solutions may be high.
- Digital Transformation: The increasing need for digital transformation in various industries provides a chance for Generix Group SA to offer its innovative solutions to companies seeking to modernize their operations.
- Partnerships and Collaborations: The company can form strategic partnerships and collaborations with other organizations to expand its product offerings, access new markets, and enhance its competitive position.
- Trends in Supply Chain Management: The evolving trends in supply chain management, such as e-commerce and omnichannel retailing, create opportunities for Generix Group SA to develop tailored solutions to meet changing customer demands.
Threats
Alongside opportunities, Generix Group SA also faces certain threats that may impact its business negatively. These threats include:
- Changing Regulatory Environment: Compliance with evolving regulations and policies can pose challenges for Generix Group SA, requiring constant monitoring and adaptation.
- Economic Instability: Economic downturns or recessions in key markets may impact customer spending and reduce demand for the company's solutions.
- New Entrants and Competitors: The entrance of new competitors or the expansion of existing competitors' offerings may intensify competition and potentially erode Generix Group SA's market share.
- Rapid Technological Changes: The rapid pace of technological advancements requires Generix Group SA to continually invest in research and development to stay ahead of competitors and meet customer expectations.
Generix Group Eulerpool Fair Value
Generix Group historical P/E ratio, EBIT multiple, and P/S ratio
Generix Group stock splits
Since 2001, a total of 2.33275 shares have been converted from one Generix Group share.
Generix Group shareholder structure
| % | Name |
|---|---|
55.58532% | |
5.64612% | |
3.56139% | |
2.20485% | |
1.37742% | |
1.07563% |
Generix Group Executives and Management Board
9 members · avg. age 59 · 33 % women
Mrs. Aida Collette-Sene
Chief Executive Officer, Managing Director, Member of the Management Board
332,159.00 EUR
Management
Mr. Francois Thery
Chief Financial Officer
Board of Directors
Mr. Jean-Charles Deconninck (62)
Chairman of the Management Board
Mr. Ludovic Luzza (43)
Group Administrative and Financial Director, Member of the Management Board
Mr. Francois Poirier (62)
Chairman of the Supervisory Board · since 2002
Mr. Dominique Despiney (70)
Independent Vice Chairman of the Supervisory Board
Ms. Viviane Chaine-Ribeiro
Independent Member of the Supervisory Board
Mr. Roland Bonnet (59)
Member of the Supervisory Board - Represented of Pleiade Investment
Frequently asked questions about Generix Group
The main competitors of Generix Group SA in the market include companies like SAP SE, Oracle Corporation, IBM Corporation, and Infor, among others.
Generix Group SA is a leading provider of collaborative business solutions for supply chain management. Their business model revolves around offering a wide range of software products and services to optimize and streamline supply chain operations. By leveraging innovative technologies, Generix Group SA assists companies in enhancing their logistics, warehouse management, transportation, and e-commerce processes. Additionally, they provide value-added services, such as data analytics and business intelligence, to help businesses make informed decisions and improve overall efficiency. Generix Group SA aims to empower organizations across various industries by delivering tailored solutions that drive operational excellence and foster growth.
Generix Group SA is primarily active in the software and technology industry.
Generix Group SA is a renowned company with a rich history and background. Founded in 1990, Generix Group SA is a leading provider of collaborative SaaS solutions for the supply chain ecosystem. The company specializes in optimizing and streamlining supply chain operations for businesses of all sizes. Generix Group SA has successfully expanded its reach internationally and now operates in more than 60 countries. With a strong focus on innovation, the company continuously develops cutting-edge technologies to meet the evolving needs of its clients. Generix Group SA's commitment to excellence and its extensive industry experience make it a trusted partner in the supply chain management sector.
Generix Group SA, a leading provider of collaborative SaaS solutions to optimize supply chain processes, has achieved significant milestones. Over the years, the company has demonstrated remarkable growth and innovation in the field of supply chain management. Generix Group SA has successfully expanded its global presence, establishing subsidiaries and partnerships worldwide. By continuously improving its software solutions, the company has enabled businesses to enhance efficiency, reduce costs, and streamline their supply chain operations. Innovations such as their Supply Chain Hub and Click&Collect solutions have solidified Generix Group SA's position as a trusted partner for businesses seeking advanced supply chain optimization.
Generix Group SA is primarily present in a wide range of countries and regions. With its global presence, the company operates in numerous countries including France, Spain, Belgium, Canada, Brazil, Mexico, and Morocco among others. As a leading international software provider, Generix Group SA continues to expand its footprint worldwide, serving clients across various industries. Through its innovative solutions, Generix Group SA aims to support businesses in optimizing their supply chain and logistics operations efficiently.
Generix Group SA is a leading company that values innovation, dedication, and customer satisfaction. With a strong corporate philosophy, Generix Group SA focuses on delivering cutting-edge technology solutions for supply chain management and digital transformation. The company aims to provide reliable and efficient services tailored to meet the unique needs of its clients. Generix Group SA remains committed to enabling businesses to adapt to the evolving market trends and enhance their operational processes. By leveraging its extensive expertise and forward-thinking approach, Generix Group SA continues to empower organizations to achieve their full potential in the constantly changing business landscape.
7 analysts currently rate the Generix Group stock: 6 recommend buying, 1 holding and 0 selling.
The Generix Group share (GENX.PA) is listed on 5 stock exchanges, including: London (0JAW.L), Frankfurt (106.F), München (106.MU), Paris (GENX.PA).
The Generix Group SA is a leading provider of business software solutions for companies around the world. With a wide range of products and services in various industries, the company offers comprehensive services for planning, implementation, and optimization of your business processes. The company is divided into four business units: Supply Chain Management (SCM), SaaS Cloud Services, Digital Transformation, and Enterprise Resource Planning (ERP). SCM is one of the most important units of Generix, offering solutions for production, distribution, and logistics. The SaaS Cloud Unit provides companies with the opportunity to manage their business processes in a secure and reliable cloud environment. The Digital Transformation Unit focuses on implementing technologies such as AI, blockchain, and IoT to improve business processes. ERP is one of the most well-known business units, providing comprehensive management solutions. Generix also offers a mobile app solution for supply chain management processes. The company collaborates with partners such as Oracle, Salesforce, and Microsoft to create customized systems for improved customer satisfaction. In summary, Generix Group SA is a leading provider of business software solutions, offering comprehensive services for planning, implementation, and optimization of business processes. The company's main areas of focus include SCM, SaaS Cloud Services, Digital Transformation, and ERP. With a focus on innovation and customer satisfaction, Generix Group SA will continue to play an important role in the global technology market.
The revenue cannot currently be calculated for Generix Group.
The profit cannot currently be calculated for Generix Group.
The P/E ratio cannot be calculated for Generix Group at the moment.
The P/S cannot be calculated for Generix Group currently.
The Eulerpool Quality Score for Generix Group is 3/10.
The ISIN of Generix Group is FR0010501692. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Generix Group is A0MYAC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Generix Group is GENX.PA. The ticker symbol is used to trade Generix Group shares on the stock exchange.
Generix Group is assigned to the 'Information technology' sector.
The dividends of Generix Group are distributed in EUR.
Generix Group stock
Generix Group Peer Group
Generix Group Ticker
Generix Group FIGI
All fundamentals and in-depth analysis of Generix Group
Our stock analysis for Generix Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Generix Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.